Form 4: Beam Therapeutics Executive Reports Stock Transaction

Amy Simon, Chief Medical Officer at Beam Therapeutics, reported a transaction involving restricted stock units.

Summary

• Amy Simon, Chief Medical Officer at Beam Therapeutics Inc., reported a transaction on March 31, 2026.
• The transaction involved the acquisition of 31,750 shares of common stock, valued at $0.00.
• These securities are restricted stock units (RSUs) granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan.
• The RSUs vest in four equal installments on the first four anniversaries of the grant date, contingent on continued service.
• Following the transaction, Amy Simon beneficially owns 109,114 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard reporting of executive stock unit grants and vesting, typical for compensation rather than a significant strategic event.

Positives

• The transaction indicates continued equity ownership and incentive alignment for a key executive.
• The vesting schedule suggests a long-term commitment to the company.

Risks

• The value of the RSUs is subject to the future performance of Beam Therapeutics' stock price.
• Vesting is contingent on continued service, meaning departure from the company would result in forfeiture of unvested RSUs.

Future Outlook

The RSUs are subject to a four-year vesting schedule, indicating a forward-looking incentive tied to continued employment and company performance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for executives and directors to report changes in beneficial ownership, reflecting typical compensation structures in the biotechnology sector.

Stakeholder Impact

• Shareholders: The transaction itself does not directly impact share price but reflects executive compensation and retention strategies.
• Employees: The RSU plan is part of the overall compensation structure for key personnel.
• Management: Reinforces the alignment of executive interests with company performance through equity incentives.

Next Steps

• The RSUs will vest in four equal installments over the next four years, subject to continued service.
• Amy Simon will continue to hold beneficial ownership of the vested shares.

Key Dates

Keywords

Beam Therapeutics, Form 4, SEC Filing, Stock Transaction, RSU, Executive Compensation, Insider Trading, Equity Incentive Plan, Chief Medical Officer